Solventum Corporation $SOLV Shares Sold by Swedbank AB

Swedbank AB lowered its holdings in Solventum Corporation (NYSE:SOLV) by 19.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,908 shares of the company’s stock after selling 8,736 shares during the quarter. Swedbank AB’s holdings in Solventum were worth $2,694,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. CYBER HORNET ETFs LLC acquired a new position in Solventum during the second quarter worth $28,000. Barrett & Company Inc. raised its holdings in shares of Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after buying an additional 268 shares during the period. IMG Wealth Management Inc. purchased a new position in Solventum during the 2nd quarter valued at about $31,000. MUFG Securities EMEA plc acquired a new position in Solventum in the 2nd quarter valued at about $31,000. Finally, State of Wyoming purchased a new stake in Solventum during the second quarter worth about $33,000.

Solventum Trading Up 0.3%

NYSE:SOLV opened at $80.45 on Friday. The company has a market capitalization of $13.95 billion, a PE ratio of 9.27, a P/E/G ratio of 8.49 and a beta of 0.26. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $88.20. The stock’s 50 day moving average price is $77.73 and its 200 day moving average price is $74.86. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same quarter in the prior year, the business earned $1.64 EPS. Solventum’s quarterly revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its board has authorized a share buyback program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 7.5% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on SOLV shares. UBS Group reiterated a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Jefferies Financial Group began coverage on Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 price objective for the company. Wells Fargo & Company raised their target price on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a report on Monday, September 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $87.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.